ArticleDrug delivery and translational research2026
Advanced lipid-based niosomes for enhanced transdermal delivery of olmesartan medoxomil via intracutaneous drug depot: a novel biomimicry approach.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Olmesartan medoxomil (OMN), a highly selective antihypertensive agent but, with problematic oral delivery due to its low solubility and limited bioavailability. Therefore, biomimetic lipid-based niosomes were adopted as a novel approach to enhance OMN solubility and boost its transdermal delivery (TD). Initially, conventional niosomes were prepared by thin film hydration method. Formulation parameters were adjusted to obtain entrapment efficiency (EE > 75%), particle size (PS < 300 nm), zeta potential (ZP > ± 25 mV), and polydispersity index (PDI < 0.5). Based on these parameters, OMN-Ns-3 was selected for further modulation. Concomitantly, screening studies of OMN in 9 liquid lipids; clove oil, Maisine
Indexed as
Identifiers
41032162What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.